Pharmaceutical Giants Invest $2.75 Billion in AI for Drug Development, Shifting from Labs to Algorithms
Loading more articles...
Big Pharma Bets Billions on AI: Eli Lilly's $2.75B Deal Reshapes Drug Discovery
C
CNBC TV18•30-03-2026, 14:46
Big Pharma Bets Billions on AI: Eli Lilly's $2.75B Deal Reshapes Drug Discovery
•Eli Lilly partners with AI biotech Insilico Medicine in a deal worth up to $2.75 billion, signaling a major shift towards AI-driven drug discovery.
•The agreement grants Lilly exclusive global rights to drug candidates discovered using Insilico’s Pharma.AI platform, with an upfront payment of $115 million.
•This partnership aims to revolutionize the inefficient traditional drug discovery model, which typically takes 10-15 years and costs $1-2 billion per drug.
•Insilico Medicine, founded in 2014, uses generative AI and deep neural networks to design new drugs, with 28 AI-designed candidates already in its pipeline.
•India is positioned to become a critical hub in the global AI-driven drug discovery value chain, leveraging its engineering, data science, and manufacturing capabilities.
